(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 17.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 21.94%.
Vericel's revenue in 2026 is $276,259,000.On average, 10 Wall Street analysts forecast VCEL's revenue for 2026 to be $16,701,639,584, with the lowest VCEL revenue forecast at $15,969,124,891, and the highest VCEL revenue forecast at $17,334,150,539. On average, 10 Wall Street analysts forecast VCEL's revenue for 2027 to be $19,701,751,737, with the lowest VCEL revenue forecast at $18,561,099,959, and the highest VCEL revenue forecast at $20,735,800,545.
In 2028, VCEL is forecast to generate $22,974,462,913 in revenue, with the lowest revenue forecast at $21,393,693,159 and the highest revenue forecast at $24,126,790,254.